Performance characteristics of the MammaPrint®breast cancer diagnostic gene signature
about
A breast cancer gene signature for indolent disease.Equivalence of MammaPrint array types in clinical trials and diagnostics.Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups.Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy.Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular SubtypingQuality assurance for multiplexed assays - how can it be achieved?
P2860
Performance characteristics of the MammaPrint®breast cancer diagnostic gene signature
description
article
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2013
@uk
name
Performance characteristics of the MammaPrint®breast cancer diagnostic gene signature
@en
Performance characteristics of the MammaPrint®breast cancer diagnostic gene signature
@nl
type
label
Performance characteristics of the MammaPrint®breast cancer diagnostic gene signature
@en
Performance characteristics of the MammaPrint®breast cancer diagnostic gene signature
@nl
prefLabel
Performance characteristics of the MammaPrint®breast cancer diagnostic gene signature
@en
Performance characteristics of the MammaPrint®breast cancer diagnostic gene signature
@nl
P2093
P2860
P356
P1476
Performance characteristics of the MammaPrint® breast cancer diagnostic gene signature
@en
P2093
Arno N Floore
Diederik Wehkamp
Laura J Van't Veer
Leonie Jm Delahaye
P2860
P304
P356
10.2217/PME.13.88
P407
P577
2013-11-01T00:00:00Z